Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer

被引:1
|
作者
Vlahovic, Ivan [1 ]
Rajc, Jasmina [2 ]
Svagelj, Ivan [3 ]
Solic, Kresimir [4 ]
Svagelj, Drazen [3 ]
机构
[1] Univ Osijek, Clin Hosp Ctr Osijek, Fac Med, Dept Abdominal Surg, Osijek, Croatia
[2] Univ Osijek, Clin Hosp Ctr Osijek, Fac Med, Dept Pathol & Forens Med, Osijek, Croatia
[3] Gen Cty Hosp Vinkovci, Dept Pathol & Cytol, Vinkovci, Croatia
[4] Univ Osijek, Fac Med, Dept Med Stat & Med Informat, Osijek, Croatia
关键词
immunohistochemistry; colorectal cancer (CRC); CDX2; dMMR; regression model; ISLAND METHYLATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLON-CANCER; E-CADHERIN; PROGNOSIS; DIFFERENTIATION; CARCINOMA; SURVIVAL; PROTEINS; FEATURES;
D O I
10.3389/pore.2023.1610908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CDX2 expression loss is commonly associated with mismatch repair deficiency (dMMR) in colorectal cancer (CRC). However, there are only a few studies that have attempted to correlate CDX2 expression loss with specific MMR genes (MLH1, MSH2, MSH6, PMS2). This is a retrospective study of 327 patients who underwent surgery due to CRC. Nine patients (2.9%) had two synchronous CRCs, making the total sample 336 CRC. Histopathological data such as tumor type, tumor grade, perineural, lymphatic, and vascular invasion, pT stage, pN stage, peritumoral and intratumoral lymphocytic infiltration were collected and recorded in the database. After immunohistochemical analysis, CDX2 expression, MLH1, MSH2, MSH6, and PMS2 deficiency were also recorded. CDX2 expression loss was detected in 19 out of 336 CRCs (5.9%) and was associated with ascending colon CRC, partially mucinous adenocarcinoma, poorly differentiated carcinoma, and dMMR. Forty-four (13.1%) of CRCs were dMMR. We found a statistically significant association between CDX2 expression loss and MLH1 and PMS2 deficiency. Considering that most expression phenotypes include pairs of MMR genes, we analyzed MLH1/PMS2 and MSH2/MSH6 as heterodimers. Analysis of heterodimers showed a similar result, namely, that MLH1/PMS2 heterodimer deficiency was significantly associated with CDX2 expression loss. We also constructed a regression model for CDX2 expression loss and for dMMR. Poor tumor differentiation and MLH1/PMS2 heterodimer deficiency have been identified as potential predictors for CDX2 expression loss. CRC in the ascending colon and CDX2 expression loss have been identified as positive potential predictors of dMMR with rectal cancer as negative potential predictor of dMMR. Our study showed a significant association between CDX2 expression loss and MLH1 and PMS2 deficiency in CRC. We also managed to produce a regression model for CDX2 expression and showed that poor tumor differentiation and MLH1/PMS2 heterodimer deficiency are independent factors for CDX2 expression loss. We were the first to include CDX2 expression in a regression model for dMMR and showed that CDX2 expression loss can be used as a predictive factor for dMMR, which should be confirmed by further studies.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The clinical perspectives of CDX2 expression in colorectal cancer: A qualitative systematic review
    Olsen, J.
    Espersen, M. L. M.
    Jess, P.
    Kirkeby, L. T.
    Troelsen, J. T.
    [J]. SURGICAL ONCOLOGY-OXFORD, 2014, 23 (03): : 167 - 176
  • [32] Pattern of expression of CDX2 in colorectal cancer and its role in prognosis.
    Singh, Jagdeep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Lack of expression of CDX2: Prognostic biomarker in stage IV colorectal cancer
    Soares, A.
    Rodrigues, D.
    Cipriano, E.
    Tavares, A.
    Vilaca, M.
    Silva, D.
    Santos, J.
    Mesquita, A.
    Salgado, M.
    Sottomayor, C.
    Almeida, R.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S136 - S136
  • [34] The microenvironment controls CDX2 homeobox gene expression in colorectal cancer cells
    Benahmed, Fairouz
    Gross, Isabelle
    Guenot, Dominique
    Jehan, Frederic
    Martin, Elisabeth
    Domon-Dell, Claire
    Brabletz, Thomas
    Kedinger, Michele
    Freund, Jean-Noel
    Duluc, Isabelle
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (02): : 733 - 744
  • [35] Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer
    Kim, SP
    Park, JW
    Lee, SH
    Lim, JH
    Jang, BC
    Lee, SH
    Jang, IH
    Freund, JN
    Suh, SI
    Mun, KC
    Song, DK
    Ha, EM
    Lee, WJ
    Kwon, TK
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 315 (01) : 93 - 99
  • [36] Expression of CDX2 in metastatic prostate cancer
    Guerrieri, C.
    Jobbagy, Z.
    Hudacko, R.
    [J]. PATHOLOGICA, 2019, 111 (03) : 105 - 107
  • [37] Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer
    Hestetun, Kjersti Elvestad
    Aasebo, Kristine
    Rosenlund, Nina Benedikte
    Mueller, Yvonne
    Dahl, Olav
    Myklebust, Mette Pernille
    [J]. MODERN PATHOLOGY, 2021, 34 (01) : 161 - 170
  • [38] Loss of CDX-2 expression is an independent poor prognostic biomarker in patients with early-stage deficient mismatch repair colorectal cancer
    Korphaisarn, Krittiya
    Sukhokanjanachusak, Kanjana
    Pongpaibul, Ananya
    Chinswangwatanakul, Vitoon
    Akewanlop, Charuwan
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (03) : 249 - 258
  • [39] CDX2 immunohistochemistry as a prognostic biomarker for colorectal cancer
    Fatimilehin, A.
    Mikropoulos, C.
    Summers, J.
    Rajakumar, L.
    Hill, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [40] The Prognostic and Predictive Utility of CDX2 in Colorectal Cancer
    Chan, Wei Yen
    Chua, Wei
    Wilkinson, Kate
    Epitakaduwa, Chandika
    Mandaliya, Hiren
    Descallar, Joseph
    Roberts, Tara Laurine
    Becker, Therese Maria
    Ng, Weng
    Lee, Cheok Soon
    Lim, Stephanie Hui-Su
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)